Exploring the Therapeutic Efficacy of Glioma Vaccines Based on Allo- and Syngeneic Antigens and Distinct Immunological Costimulation Activators

Apostolos Stathopoulos^1,2,7*, Chrystel Pretto², Laurent Devillers², Denis Pierre², Florence M. Hofman³, Alan L. Epstein³, Hooman Farghadani⁸, Carol A. Kruse⁴, Martin R. Jadus⁵, Thomas C. Chen^2,7 and Virgil E.J.C. Schijns^2,6*

¹Department of Neurosurgery, Arlon Hospital, Arlon, Belgium

²Epitopoietic Research Corporation (ERC), Namur, Belgium

³Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA

⁴Department of Neurosurgery, University of California, Los Angeles, California and the Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA 90095, USA

⁵Veterans Affairs Medical Center, Long Beach, CA 90822, box 113, 5901 E7th St. and Chao Cancer Center, University of California, Irvine, Orange CA, USA

⁶Cell Biology & Immunology Group, Wageningen University, PO Box 338, 6700 AH Wageningen, The Netherlands

⁷Department of Neurosurgery, University of Southern California, Keck School of Medicine, Los Angeles, California, USA

⁸Department of General Surgery, Arlon Hospital, Arlon, Belgium

^*Corresponding Author(s): Dr. Apostolos Stathopoulos, Department of Neurosurgery, Arlon Hospital, Arlon, Belgium Email: Dr. Virgil E.J.C. Schijns, Cell Biology & Immunology Group, Wageningen University, PO Box 338, 6700 AH Wageningen, The Netherlands Email: